Sec Form 4 Filing - Bedoya-Toro Munera Maria E @ Dermata Therapeutics, Inc. - 2021-08-17

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Bedoya-Toro Munera Maria E 2. Issuer Name and Ticker or Trading Symbol Dermata Therapeutics, Inc. [ DRMA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Senior Vice President (Last) (First) (Middle) 3525 DEL MAR HEIGHTS RD., #332 3. Date of Earliest Transaction (MM/DD/YY) 08/17/2021 (Street) SAN DIEGO, CA92130 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/17/2021 C 9,162 A 28,674 I By Munera Family Trust ( 7 ) Common Stock 08/17/2021 C 19,512 A 48,186 I By Munera Family Trust ( 7 ) Common Stock 08/17/2021 C 4,878 A 53,064 I By Munera Family Trust ( 7 ) Common Stock 08/17/2021 C 17,421 A 70,485 I By Munera Family Trust ( 7 ) Common Stock 08/17/2021 C 13,658 A 84,143 I By Munera Family Trust ( 7 ) Common Stock 30,487 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series 1d Preferred Stock ( 1 ) 08/17/2021 C 61,821 ( 1 ) ( 1 ) Common Stock 9,162 $ 0 0 I By Munera Family Trust ( 7 ) Series 1a Preferred Stock ( 2 ) 08/17/2021 C 400,000 ( 2 ) ( 2 ) Common Stock 19,512 $ 0 0 I By Munera Family Trust ( 7 ) Series 1b Preferred Stock ( 3 ) 08/17/2021 C 100,000 ( 3 ) ( 3 ) Common Stock 4,878 $ 0 0 I By Munera Family Trust ( 7 ) Series 1c Preferred Stock ( 4 ) 08/17/2021 C 357,142 ( 4 ) ( 4 ) Common Stock 17,421 $ 0 0 I By Munera Family Trust ( 7 ) Series 1 Preferred Stock ( 5 ) 08/17/2021 C 280,000 ( 5 ) ( 5 ) Common Stock 13,658 $ 0 0 I By Munera Family Trust ( 7 ) Series 1a Warrants ( 6 ) 08/17/2021 C 100,000 11/15/2016 03/14/2026 Common Stock 4,878 $ 0 0 I By Munera Family Trust ( 7 ) Warrant to Purchase Common Stock $ 20.5 08/17/2021 C 4,878 11/15/2016 03/14/2026 Common Stock 4,878 $ 0 4,878 I By Munera Family Trust ( 7 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Bedoya-Toro Munera Maria E 3525 DEL MAR HEIGHTS RD., #332 SAN DIEGO, CA92130 Senior Vice President Signatures /s/ Gerald T. Proehl, Attorney-in-Fact 08/17/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. ( 2 )The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. ( 3 )The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. ( 4 )The Series 1c Preferred Stock co nverted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. ( 5 )The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. ( 6 )The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO. ( 7 )Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.